



VIA HAND DELIVERY JANUARY 25, 2001

43/C
Dmt
2-6-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Moore et al.

Application Serial No.: 09/376,430

Art Unit: 1646

Filed: August 18, 1999

Examiner: O'Hara, E.

For: **Cytokine Receptor Common
Gamma Chain Like**

Attorney Docket No.: PF466P1

RECEIVED
FEB 05 2002
TECH CENTER 1600/2900

PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, D.C. 20231

Sir:

Prior to examination on the merits, Applicants hereby request that the following remarks be entered into the above-captioned application. Applicants submit concurrently herewith: (a) a Request for Continued Prosecution Application Transmittal; (b) a Fee Transmittal Sheet; and (c) a Petition for Extension of Time for three (3) months up to and including January 27, 2002. Please amend the application as follows:

In the claims:

Please add the following new claim 102:

C1
102. (New) An isolated protein comprising a polypeptide selected from the group consisting of:

Sub D6
(a) a polypeptide consisting of amino acid residues +1 to +371 of SEQ ID NO:2, in which 1 or more amino acid residues are substituted, deleted or added, in any combination and wherein said polypeptide binds an antibody specific for the polypeptide of SEQ ID NO:2;

(b) a polypeptide consisting of a fragment of SEQ ID NO:2 which fragment has immune cell proliferative activity and in which 1 or more amino acid residues are substituted, deleted or added, in any combination; and

21
Sub D6
(c) a polypeptide consisting of a fragment of SEQ ID NO:2 which
fragment has immune cell proliferative activity and in which 1 or more amino acid residues
are substituted, deleted or added, in any combination and wherein said polypeptide binds an
antibody specific for the polypeptide of SEQ ID NO:2.

Add D7